Skip to main content
Delfa

← Trials/Trial dossier/NCT00726726

CompletedPhase 1

Drug Interaction Study With a Potential Alzheimer's Disease Compound

Effect of Concomitant Administration of BMS-708163 on the Pharmacokinetics of Midazolam, Warfarin, Caffeine, Omeprazole and Dextromethorphan in Healthy Male Subjects by Administration of a Modified Cooperstown Cocktail

Asset

Avagacestat

Listed sites

1

Recruiting sites

-

Enrollment

22

actual

Study population

Alzheimer’s disease

Key I/E criteria

•Age 18-45•Male

Primary endpoint

•Pharmacokinetic effects of BMS-708163 on interacting drugs

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDCN156-005
NCT IDNCT00726726

Timeline

Milestones

Study first posted2008-08-01estimated
Study start2008-08 (month precision)
Primary completion2008-10actual (month precision)
Study completion2008-10actual (month precision)
Last update posted2008-11-05estimated

Assets

Drug assets

Avagacestat

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age18 Years
Maximum age45 Years
SexMale
Healthy volunteersAccepted

Inclusion criteria

•Healthy male subjects
•18-45 yrs old inclusive

Exclusion criteria

•Women

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

2 endpoints
Primary/protocol endpoint

Pharmacokinetic effects of BMS-708163 on interacting drugs (midazolam, warfarin, caffeine, omeprazole, and dextromethorphan)

Time frame:throughout the study

descriptive

Secondary/protocol endpoint

Safety variables (adverse events, vital signs, safety labs)

Time frame:throughout the study

event count, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.